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Background: Brazil has sought to use economic evaluation to support healthcare 
decision-making processes. While a number of health economic evaluations (HEEs) 
have been conducted, no study has systematically reviewed the quality of Brazilian HEE. 
The objective of this systematic review was to provide an overview regarding the state 
of HEE research and to evaluate the number, characteristics, and quality of reporting of 
published HEE studies conducted in a Brazilian setting.
methods: We systematically searched electronic databases (MEDLINE, EMBASE, Latin 
American, and Caribbean Literature on Health Sciences Database, Scientific Electronic 
Library Online, NHS Economic Evaluation Database, health technology assessment 
Database, Bireme, and Biblioteca Virtual em Saúde Economia da Saúde); citation 
indexes (SCOPUS, Web of Science), and Sistema de Informação da Rede Brasileira de 
Avaliação de Tecnologia em Saúde. Partial and full HEEs published between 1980 and 
2013 that referred to a Brazilian setting were considered for inclusion.
Results: In total, 535 studies were included in the review, 36.8% of these were 
considered to be full HEE. The category of healthcare technologies more frequently 
assessed were procedures (34.8%) and drugs (28.8%) which main objective was 
treatment (72.1%). Forty-four percent of the studies reported their funding source 
and 36% reported a conflict of interest. Overall, the full HEE quality of reporting was 
satisfactory. But some items were generally poorly reported and significant improve-
ment is required: (1) methods used to estimate healthcare resource use quantities and 
unit costs, (2) methods used to estimate utility values, (3) sources of funding, and (4) 
conflicts of interest.
conclusion: A steady number of HEE have been published in Brazil since 1980. To 
improve their contribution to inform national healthcare policy efforts need to be made to 
enhance the quality of reporting of HEEs and promote improvements in the way HEEs 
are designed, implemented (i.e., using sound methods for HEEs) and reported.
Keywords: economic evaluation, cost-effectiveness, Brazil, cost-benefit analysis, health technology assessment
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iNtRODUctiON
Brazil is an upper middle-income country with a population 
of 200 million citizens, largely urban (85%). It is a federative 
republic with 26 states, a federal district, and 5,564 municipali-
ties. The 1998 Brazilian Constitution offered the right to health 
for all citizens, and created the Unified Health System (SUS): a 
public system directed at provision of universal, comprehensive, 
collective, and individual healthcare. The major SUS funders are 
federal, states, and cities governments, through taxes and social 
contributions. Public and private providers deliver services 
which are free at the point of delivery. The private sector covers 
approximately 25% of the population (48 million people), and 
dominated by an emergent health insurance market (1).
In 2014, Brazil had a gross domestic product (GDP) per capita 
of US$15,200, and approximately 9% of its GDP was spent on 
healthcare. The health expenditure per capita is US$1,109, and 
46% of this is funded by public sources (2). The SUS public 
health financing is considered insufficient, and the equilibrium 
between public and private systems is challenging with consider-
able funds flowing from public coffers to private providers (3).
Resource scarcity is a reality in the Brazilian health system. 
Due to this scarcity, efficient allocation of resources is essential. 
Economic evaluation methods in healthcare have evolved as an 
important tool to assess the costs and benefits of health technolo-
gies and help decision-makers inform efficient allocation.
Brazil has sought to use economic evaluation to support 
decision making for rational management of the health system. 
The Ministry of Health, through the Department of Science and 
Technology (DECIT), has fostered the development of economic 
evaluation studies. Since 2006, DECIT has collaborated with the 
Committee on Incorporation of Technologies of the Ministry of 
Health (CITEC), an health technology assessment (HTA) body 
responsible for evaluating the incorporation of new technolo-
gies by SUS (4). In 2011, CITEC was replaced by the National 
Incorporation of Technologies in SUS, CONITEC, introduced 
the requirement for health economic evaluation (HEE) studies 
either to help inform policy recommendations for the adoption 
of new technologies or to review policy recommendations made 
by SUS (5, 6). The first Brazilian guideline for HEE studies was 
published in 2009, but the concept of a reference case has not been 
prescriptively adopted in Brazil yet. The revised HEE Brazilian 
guideline (7) issued by the Ministry of Health in 2014, presents 
some recommendations that broadly agree on many methodo-
logical specifications of the National Institute for Health and Care 
Excellence reference case.
In recent decades, a large amount of local HEE studies have 
been published. There is a strong evidence of the upward stream 
of blossoming in HEE publications and its acceleration (8). The 
evolution of scientific literature in health economics published in 
Brazil between 1986 and 2007 has been evaluated and reported 
in the published literature (9–11). Recently, Brazil appeared 
among the top 15 countries in HE research, accounting for 
1.7% of identified records, and has been identified as the South 
American country that published the largest number of HEE 
studies (8, 12, 13).
Systematic reviews of country-specific HEE studies were con-
ducted earlier in other countries including developed countries, 
Latin America, Asian, and African countries (14–28).
While a number of HEE have been conducted in Brazil, no 
study has systematically reviewed the quality of Brazilian HEE. 
The objective of this systematic review was to assess the state of 
the HEE research capacity development in Brazil and the ability 
to conduct good quality HEE. Specifically, this review evaluated 
the number, characteristics, and quality of reporting of published 
economic studies in a Brazilian setting.
mateRiaLS aND metHODS
This study followed the guidelines for systematic review of HEE 
studies published by the Centre for Reviews and Dissemination 
(CRD) and the preferred reporting items for systematic reviews 
and meta-analyses statement (29, 30). The protocol is available 
from the authors on request.
Systematic Search and identification of 
Relevant Studies
A broad and exhaustive strategy search was formulated in order 
to identify all relevant studies published between January 1980 
and December 2013. We systematically searched the following 
electronic data bases: MEDLINE (via PubMed), EMBASE, Latin 
American, and Caribbean Literature on Health Sciences Database, 
Scientific Electronic Library Online, NHS Economic Evaluation 
Database, HTA Database (CRD), Bireme, and Biblioteca Virtual 
em Saúde Economia da Saúde; citation indexes: SCOPUS, Web 
of Science, and the Sistema de informação da Rede Brasileira de 
Avaliação Tecnologia e Saúde (SISREBRATS). We also performed 
manual searches from the reference lists of included articles, and 
all issues of the Brazilian Journal of Health Economics (BJHE), 
a non-indexed journal in the previously mentioned databases 
in 2013.
The search strategy was reviewed by a librarian specialist 
and combined subject headings (MeSH and EMTREE) and free 
text terms (“Health Economics” OR “Economics, Hospital” OR 
“Economics, Medical” OR “Economics, Nursing” OR “Economics, 
Pharmaceutical” OR “Economics” OR “costs and cost analysis” 
OR “Cost” OR “Cost savings” OR “Cost of illness” OR “Analyses, 
Cost-Benefit” OR “Analysis, Cost-Benefit” OR “Cost-Benefit 
Analyses” OR “Cost Benefit Analysis” OR “Analyses, Cost Benefit” 
OR “Analysis, Cost Benefit” OR “Cost Benefit Analyses” OR “cost 
Effectiveness” OR “Effectiveness, Cost” OR “cost effectiveness 
analysis” OR “cost-Benefit Date” OR “cost Benefit Date” OR 
“Date, Cost-Benefit” OR “cost Benefit” OR “Benefits and Costs” 
Abbreviations: HEEs, health economic evaluations; SUS, Unified Health System; 
GDP, gross domestic product; DECIT, Department of Science and Technology; 
CITEC, Committee on Incorporation of Technologies of the Ministry of Health; 
CONITEC, National Incorporation of Technologies in SUS; NICE, National Institute 
for Health and Care Excellence; CCA, cost-consequences analysis; CMA, cost-
minimization analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; 
CBA, cost-benefit analysis; CHEERS, Consolidated Health Economic Evaluation 
Reporting Standards; HTA, health technology assessment; BJHE, Brazilian Journal 
of Health Economics; SISREBRATS, Sistema de Informação da Rede Brasileira de 
Avaliação de Tecnologia em Saúde; QALY, quality-adjusted life year.
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OR “Costs and Benefits”) for “economic/cost” concept with sub-
ject headings (MeSH and EMTREE) and free text terms (“Brazil” 
OR “Brazilian” OR “Brazi*”) for “Brazil” concept. Keywords were 
matched to database specific indexing terms, taking into account 
the change in the indexing or classification of economic studies 
in different databases.
eligibility: Selection criteria
Articles were included if they were partial or full HEE according 
to internationally recognized criteria (31, 32), referred to the 
Brazilian setting, and at least one of the authors was Brazilian 
and affiliated to a Brazilian institution. Multicenter studies, where 
Brazil was one of the participating countries, as well as studies 
conducted on Brazil by foreign authors, were excluded.
Studies were considered partial HEE if they examined only 
costs (cost description), described costs of a particular disease 
to society (cost of illness), described costs and outcomes of a 
single service or program (cost-outcome description), described 
financial consequences of technology adoption [budget impact 
analysis (BIA)] or compared only costs of two or more interven-
tions (cost analysis). Studies were considered full HEE if they 
compared costs and consequences of two or more healthcare 
interventions alternatives, including cost-consequences analysis 
(CCA), cost-minimization analysis (CMA), cost-effectiveness 
analysis (CEA), cost-utility analysis (CUA), and cost-benefit 
analysis (CBA).
Abstracts, editorials, letters, posters and congress communica-
tions, methodological, discussion and review articles, and eco-
nomic evaluation of other than health technologies (for example, 
environment) were excluded.
The titles and abstracts of identified citations were screened 
for relevance independently by two reviewers (Tassia Cristina 
Decimoni and Roseli Leandro). Disagreements were resolved 
through discussion or through consultation with a third reviewer 
(Patrícia Coelho de Soárez). Full texts of selected and those for 
which inclusion was in doubt were retrieved and independently 
screened by both reviewers.
Data extraction
Two reviewers (Tassia Cristina DecimoniTCD and Roseli 
Leandro) independently extracted data from each of the included 
studies on year and journal of publication, economic evaluation 
type, category of technology assessed (drugs, vaccines, equip-
ment, clinical, surgical and diagnostic procedures, public health 
and health promotion programs), objective of the technology 
assessed (treatment, prevention, screening, and diagnosis), 
health problem studied (International statistical classification of 
diseases and related health problems, 10th revision, ICD-10) (33), 
first author affiliation (academy, government, research institutes, 
health organization, consulting, pharmaceuticals or equipment 
industry, international body), region of the first author, source 
of funding (research funding agencies, government, consulting, 
pharmaceuticals, or equipment industry), and authors’ conflict 
of interest. Conflict of interest was defined according to Valachis 
et al. (34) who argued that an author may need to declare having 
a conflict of interest in if she/he has received remuneration in 
payment or in kind (e.g., stocks or shares) from the manufacturer 
as a result of any of the following: research support or employ-
ment contract (salary, equipment, supply, reimbursement for 
participation in symposia, and other expenses), or consulting 
services.
In addition to the above, the standardized extraction form used 
also contained 17 questions from a systematic review of quality 
assessment tools (35), and the Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) instrument (36). 
These questions were intended to assess the quality of reporting 
of full HEE. Quality was defined as the extent to which a study 
complied and reported items included in the quality assessment 
tool and CHEERS checklist mentioned above (35, 36). The qual-
ity of the sources of evidence used in the studies was assessed 
with the hierarchy proposed by Coyle and Lee (37, 38). Where 
data sources ranked 1 are considered to be the most appropri-
ate source (highest quality), and those assigned a rank of 6 are 
considered the least appropriate (lowest quality) (39) (Table 1). 
Disagreements on the extracted data were resolved through dis-
cussion or through consultation with a third reviewer (Patrícia 
Coelho de Soárez).
Data Summary
Data were summarized using qualitative narrative synthesis. The 
study characteristics are summarized in figures and summary 
tables.
Data analysis
Data analysis was performed with descriptive statistics such as 
absolute frequencies (raw counts) for each category of the discrete 
variable, relative frequencies (proportions or percentages of the 
total number of observations), along with analytic statistics that 
included Pearson correlations to investigate the relationship 
between the quality of reporting of the full HEE and the pub-
lication time period (1980–2005, 2006–2009, and 2010–2013), 
conflict of interest and source of funding. The publication time 
periods were chosen because they represent three different stages 
of the HTA in Brazil (1980–2005: before the establishment of 
the General Coordination Office for HTA; 2006–2009: establish-
ment of CITEC; 2010–2013; after the publication of the Brazilian 
guideline for HEE studies). Linear regression models were used 
to evaluate changes in study characteristics over time. Data 
analyses were conducted using STATA/SE version 12.1 (Stata 
Corp, College Station, USA). An alpha level of 5% was used for 
statistical significance (P ≤ 0.05).
ReSULtS
Literature Search
In total 11,841 records were identified from database searches, 
and 105 further articles were identified through hand-searching 
in BJHE, SISREBRATS, and other sources. Figure  1 depicts a 
flow diagram with full details of searches output, and reasons for 
inclusion/exclusion. We identified 9,304 non-duplicate citations, 
of which 721 were recognized as potentially relevant and full 
papers were retrieved. Out of the 721 studies 186 of them were 
excluded, reasons for exclusion included: thesis (50 studies), not 
taBLe 1 | Hierarchies of data sources for health economic evaluation studies modified from Coyle and Lee (37–39).
Rank Data components
clinical effect sizes, adverse events, and complications
1+ Meta-analysis of RCTs with direct comparison between comparator therapies measuring final outcomes
1 Single RCT with direct comparison between comparator therapies measuring final outcomes
2+ Meta-analysis or RCTs with direct comparison between comparator therapies measuring the surrogate outcomes
Meta-analysis or placebo-controlled RCTs with similar trial populations, measuring final outcomes for each individual therapy
2 Single RCT with direct comparison between comparator therapies measuring the surrogate outcomes
Single placebo-controlled RCTs with similar trial populations, measuring final outcomes for each individual therapy
3+ Meta-analysis or placebo-controlled RCTs with similar trial populations, measuring the surrogate outcomes
3 Single placebo-controlled RCTs with similar trial populations, measuring the surrogate outcomes for each individual therapy
4 Case control or cohort studies
5 Nom-analytic studies, for example, case reports, case series
6 Expert opinion
Resource use
1 Prospective data collection or analysis of reliable data for specific study
2 Recently published results of prospective data collection or recent analysis of reliable administrative data—same jurisdiction
3 Unsourced data from previous economic evaluation—same jurisdiction
4 Recently published results of prospective data collection or recent analysis of reliable administrative data—different jurisdiction
5 Unsourced data from previous economic evaluation—different jurisdiction
6 Expert opinion
costs
1 Cost calculations based on reliable databases or data sources conducted for specific study—same jurisdiction
2 Recently published cost calculations based on reliable databases or data sources—same jurisdiction
3 Unsourced data from previous economic evaluation—same jurisdiction
4 Recently published cost calculations based on reliable databases or data sources—different jurisdiction
5 Unsourced data from previous economic evaluation—different jurisdiction
6 Expert opinion
Utilities (if applicable)
1 Direct utility assessment for the specific study from a sample either:
(a) of the general population
 (b) with knowledge of the disease(s) of interest
 (c) of patients with the disease(s) of interest 
Indirect utility assessment from specific study from patient sample with the disease(s) of interest, using a tool validated for the patient population
2 Indirect utility assessment from a patient sample with the disease(s) of interest, using a tool not validated for the patient population
3 Direct utility assessment from previous study from a sample either:
 (a) of the general population
 (b) with knowledge of the disease(s) of interest
 (c) of patients with the disease(s) of interest 
Indirect utility assessment from previous study from patient sample with the disease(s) of interest, using a tool validated for the patient population
4 Unsourced utility data from previous study—method of elicitation unknown
5 Patient preference values obtained from a visual analog scale
6 Delphi panels, expert opinion
RCT, randomized control trial.
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According to internationally agreed classifications of HEE 
studies (31, 32), more than half of included studies were partial 
HEE (63.2%, 338/535). Of these, the majority (66%, 223/338) 
were cost description followed by cost analysis studies (32.2%, 
109/338). Of the 197 full HEE, 39.1% (77/197) were CEA, 20.3% 
(40/197) were CCA, 11% (21/197) were CEA and CUA, 8.6% 
(17/197) were CUA, 7.1% (14/197) were CMA, and 4.6% (9/197) 
were CBA. Nine percent (19/197) of the studies concurrently 
performed more than one type of analysis. CMA evaluated 
mainly medications (corticosteroids, antihistamines, antibiotics, 
biologics, monoclonal antibodies, tyrosine kinase inhibitors, 
chemotherapeutics, anticoagulants, etc.). Prior to 2008, the 
HEE (88 studies), no Brazilian author (19 studies), reviews (18), 
and other (11 studies), see Figure  1 for detailed description. 
Scientific papers derived from excluded thesis and reports were 
included.
Study characteristics
The publication of HEE studies in Brazil started in the 1980s. 
Since then, there has been an upward trend with a slight increase 
at the end of the 1990s, and a sharp increase in 2007 with the 
publication of 356 (67%, 356/535) articles (Figure 2). A total of 
535 studies were identified as suitable for inclusion in this review 
and their characteristics are described in Table 2.
FiGURe 1 | Flow diagram of health economic evaluation studies in Brazil, 1980–2013.
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majority of published evaluations were partial HEE. From 2008 
onward, there was an increase in the number of full HEE, and 
the distribution of full and partial HEE studies became almost 
equivalent. An initial increase in the number of CEA studies has 
been followed by a sharp rise in the number of CUA, these have 
almost quadrupled in the last 3  years. The proportion of CUA 
studies increased from 17.6% between 2004 and 2009 to 82.4% 
between 2010 and 2013 (P = 0.028) (Table 2; Figure 3). Out of 
the 535 included studies, nearly half (n =  248, 46.3%) did not 
report the type of HEE study performed. Among these, 228 were 
partial and 20 were full HEE.
The review indicated an issue with the classification of study 
design in the identified HEE studies. According to international 
criteria (31, 32) of the 287 HEE that reported study type, 28.5% 
(82/287) had been classified incorrectly. Fifty-two (63.4%, 52/82) 
were partial analysis and 36.6% (30/82) full analysis. The most 
frequent misclassification among full HEE was to describe studies 
as CEA, where on investigation they were found to be CCA (53%, 
16/30). Similarly, partial analyses described as cost analyses were 
cost descriptions (33%, 17/52). Some studies reported as CBA 
only performed cost analyses (29%, 15/52). Finally, some studies 
described as cost descriptions were cost analyses (15%, 8/52).
FiGURe 2 | Number of health economic evaluation studies in Brazil, by type, 1980–2013.
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The categories of healthcare technologies that were most 
frequently assessed were procedures (34.8%, 186/535) and drugs 
(28.8%, 154/535). The proportion of studies that evaluate proce-
dures increased from 4.3% during the 1980s to 39.2% between 
2010 and 2013 (P  =  0.002). Technologies assessed included 
treatment (72.1%, 386/535), prevention (8.6%, 46/535), and 
diagnostic and treatment (6%, 32/535).
The technologies evaluated in the studies were mainly related 
to the group of diseases of the Chapter I—certain infectious and 
parasitic diseases of ICD-10 (17.4%, 93/535), followed by Chapter 
IX—diseases of the circulatory system (12.9%, 69/535), Chapter 
II—neoplasms (10.3%, 55/535), and Chapter IV—endocrine, 
nutritional, and metabolic diseases (9.2%, 49/535).
Studies by authorship, Journal, Funding 
Source, and conflict of interest
In most of the studies evaluated, the first authors were affiliated to 
academic institutions (65.1%, 348/535), followed by health organ-
izations (19.8%, 106/535), public administration (5.8%, 31/535), 
consultancy firms (4.5%, 24/353), pharmaceuticals or equipment 
industry (2.8%, 15/535), research institutes (1.9%, 10/535), and 
international organizations (0.2%, 1/535). Although in the major-
ity of publications, the first author was affiliated to an academic 
institution, there has been an increase of first authors affiliated to 
health organizations and consultancy firms (Figure 4).
The majority of Brazilian HEE studies were published in 
medical (55.5%, 297/535), and, public health (20%, 107/535) 
journals. Only 11.9% (64/535) were published in specialized 
health economics journals. Three hundred and eighty-eight 
studies (72.5%, 388/535) were published in Brazilian journals. Of 
those, 10.6% (41/388) were published in a non-indexed journal.
Regarding the geographical distribution of the first authors, 
southeast region stands out as a major producer of HEE (73.6%), 
followed by south (12.5%), and northeast (8.2%). The proportion 
of publications by regions remained constant during the study 
period. São Paulo and Rio de Janeiro were the Brazilian states 
more productive, 51.6 and 14.6%, respectively.
Two hundred and thirty-four studies (44%, 234/535) reported 
the funding source, among these, 12.4% (29/234) reported no 
funding and 87.6% (205/234) reported some funding source. 
Of these, 39% (80/205) were funded by research agencies, 32% 
(65/205) by industry, 15% (31/205) by the government, and 14% 
(29/205) had other or multiple funding sources.
Of the 535 studies included in the review, 36% (193/535) 
declared a conflict of interest, 82% (159/193) declared no conflict 
of interest. Of the 159 studies that declared no conflicts of interest, 
13% (21/159) were considered (according to Valachis et al.) (34) 
to have a potential conflict of interest due to authors being indus-
try or consultancy firm employees. Similarly, applying Valachis 
criteria to all 535 included studies, 84% (449/535) would be con-
sidered to not have a conflict of interest and 16% (86/535) could 
be considered to have a conflict of interest. Identified reasons for 
potential conflict of interest were: 49% (42/86) were developed 
by consultancy firms and industry; 45% (39/86) had at least one 
author contractually employed by the industry or funded by it; 
and 6% (5/86) were related to consultancy work.
Compliance with international recommendations for good 
reporting in the 197 studies identified as full HEE are presented 
in Figure 5. Most studies complied with the following items clearly 
stated: the research question (100%), competing alternatives (99%), 
primary outcome measure (95%), source of effectiveness estimates 
(94%), type of model (92%), and economic study design (90%).
Studies by Reporting Quality and Quality 
of the Sources of evidence
Thirty-two percent (63/197) of the studies did not state a perspec-
tive for their analysis. Only 37% (73/197) described the methods 
for the estimation of total volume of healthcare resources used in 
taBLe 2 | Characteristics of health economic evaluation (HEE), according time period, Brazil, 1980–2013.
characteristics 1980–1989 1990–1999 2000–2004 2005–2009 2010–2013 total P-value
type of Hee
Partial N(%) N(%) N(%) N(%) N(%) N(%)
Cost description 11 (4.9) 15 (6.7) 37 (16.6) 64 (28.7) 96 (43.0) 223 (100) 0.133
Cost analysis 5 (4.6) 11 (10.1) 23 (21.1) 35 (32.1) 35 (32.1) 109 (100) 0.155
Cost-outcome description 1 (25.0) – 1 (25.0) – 2 (50.0) 4 (100) 0.472
Cost analysis and BIA – – – – 2 (100) 2 (100) 0.183
Total 17 (5.0) 26 (7.7) 61 (18.0) 99 (29.3) 135 (39.9) 338 (100) 0.168
Full N(%) N(%) N(%) N(%) N(%) N(%)
Cost-effectiveness analysis 2 (2.6) – 4 (5.2) 26 (33.8) 45 (58.4) 77 (100) 0.150
Cost-consequence analysis – 6 (15.0) 8 (20.0) 12 (30.0) 14 (35.0) 40 (100) 0.0001
CEA and CUA – 1 (4.8) – 5 (23.8) 15 (71.4) 21 (100) 0.150
Cost–utility analysis – – – 3 (17.6) 14 (82.4) 17 (100) 0.028
Cost-minimization analysis 2 (14.3) 1 (7.1) 1 (7.1) 4 (28.6) 6 (42.9) 14 (100) 0.03
Cost-benefit analysis – 2 (22.2) – 1 (11.1) 6 (66.7) 9 (100) 0.133
More than one – 1 (5.3) 1 (5.3) 4 (21.1) 13 (68.4) 19 (100) 0.355
Total 4 (2.0) 11 (5.6) 14 (7.1) 55 (27.9) 113 (57.4) 197 (100) 0.995
type of technology N(%) N(%) N(%) N(%) N(%) N(%)
Procedures 8 (4.3) 20 (10.8) 35 (18.8) 50 (26.9) 73 (39.2) 186 (100) 0.002
Medications 8 (5.2) 4 (2.6) 14 (9.1) 50 (32.5) 78 (50.6) 154 (100) 0.063
Procedures and medications 3 (4.6) 1 (1.5) 8 (12.3) 17 (26.2) 36 (55.4) 65 (100) 0.132
Public health and health promotion programs – 4 (8.5) 4 (8.5) 14 (29.8) 25 (53.2) 47 (100) 0.176
Devices 1 (4.3) 2 (8.7) 5 (21.7) 7 (30.4) 8 (34.8) 23 (100) 0.287
Vaccines – 3 (14.3) 2 (9.5) 8 (38.1) 8 (38.1) 21 (100) 0.777
Procedure, medications, and devices – 1 (8.3) 1 (8.3) 4 (33.3) 6 (50.0) 12 (100) 0.564
Equipment – 1 (33.3) 1 (33.3) – 1 (33.3) 3 (100) 0.251
Other 1 (4.2) 1 (4.2) 5 (20.8) 4 (16.7) 13 (54.2) 24 (100) 0.795
Objective N(%) N(%) N(%) N(%) N(%) N(%)
Treatment 18 (4.7) 22 (5.7) 55 (14.2) 115 (29.8) 176 (45.6) 386 (100) 0.796
Prevention – 5 (10.9) 4 (8.7) 16 (34.8) 21 (45.7) 46 (100) 0.588
Diagnostic and treatment – – 8 (25.0) 6 (18.8) 18 (56.3) 32 (100) 0.197
Diagnostic 1 (3.2) 4 (12.9) 2 (6.5) 9 (29.0) 15 (48.4) 31 (100) 0.989
Screening – 2 (15.4) – 4 (30.8) 7 (53.8) 13 (100) 0.591
Prevention and treatment – 2 (40.0) 1 (20.0) 1 (20.0) 1 (20.0) 5 (100) 0.079
Screening, diagnostic, and treatment – – 1 (100) – – 1 (100) 0.336
Other 2 (9.5) 2 (9.5) 4 (19.0) 3 (14.3) 10 (47.6) 21 (100) 0.278
Total 21 (3.9) 37 (6.9) 75 (14.0) 154 (28.8) 248 (46.4) 535 (100) 0.734
BIA, budget impact analysis; CEA, cost-effectiveness analysis; CUA, cost-utility analysis; more than one: 19 studies concurrently performed more than one type of analysis: 13 
studies CEA and BIA; 1 study CMA and BIA; 1 study CUA and CBA; 1 study CEA and CBA; 1 study CMA and CBA; 1 study CEA, CUA, and BIA; 1 study CMA, CBA, and CCA.
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a transparent manner (i.e., reporting quantities and prices/unit 
costs separately). Less than half (43%, 85/197) of the studies stated 
the discount rate applied. Other identified caveats associated with 
studies’ reporting were: failure to declare a conflict of interest, 
not stating a time horizon for the analysis, omitting to perform, 
and describe a sensitivity analysis. Of the 197 full HEE, 64.5% 
(127/197) were model-based economic evaluation. Of these, 
92.1% (117/127) reported the type of model used: 41.9% (49/117) 
used Markov models, 34.2% (40/117) used decision trees, 6% 
(7/117) used Markov models with decision trees, 6% (7/117) 
dynamic models, and 12% (14/117) used other types of models.
The reporting quality association with the publication period 
was statistically significant (P <  0.001). The reporting quality 
increased progressively during the study period. Most recent peri-
ods showed better reporting quality. Studies published between 
2010 and 2013 showed better reporting quality compared with 
those published between 2005 and 2009 and those published 
between 1980 and 2004. No association was found between the 
reporting quality and the study source of funding. Moreover, 
positive association was observed between the reporting qual-
ity and the variable conflict of interest. Studies with conflict of 
interest are associated with a better reporting quality (P < 0.001).
The quality of the sources of evidence used in the studies 
performed in the Brazilian setting was analyzed in depth using 
the hierarchy proposed by Coyle and Lee (37–39). Figure  6 
presents a graphical representation of results from this analysis. 
Our findings suggest that poorer quality of information was 
available for estimating utilities values than costs, resource use, 
and clinical effect size. No study directly (e.g., via a health state 
preference evaluation exercise) or indirectly (e.g., used utility 
FiGURe 4 | Number of health economic evaluation studies in Brazil, by first author affiliation, 1980–2013.
FiGURe 3 | Full health economic evaluation published in Brazil, 1980–2013. More than one: cost-effectiveness analysis (CEA) and budget impact analysis (BIA); 
cost-minimization analysis (CMA) and BIA; CMA, cost-benefit analysis (CBA), and cost-consequences analysis (CCA); ACU and ACB; CMA and CBA; CEA, 
cost-utility analysis (CUA), and BIA.
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values from an alternative patient sample but with the disease 
of interest) performed utility assessment. Twenty-two percent of 
the studies estimated utilities parameters from a previous study, 
37% had data source or method of elicitation unknown, 12% was 
based on expert opinion, and 29% was not possible to evaluate. 
In contrast to utility value estimates data on costs, resource use 
and clinical effect size were mostly estimated using high-ranked 
evidence. For instance, more than 50% of the studies used cost 
information from sources where quality was ranked as 1+, 1, 2+, 
2. Costs calculations were mainly based on reliable administrative 
database or data sources conducted for the specific study, and on 
recently published cost calculations based on reliable databases. 
Similarly, in 58% of the studies clinical effect sizes were estimated 
from meta-analysis or RCTs.
DiScUSSiON
To the best of our knowledge, this the first systematic review 
describing the number, characteristics, and quality of reporting 
of HEE studies in Brazil.
The absolute number of all HEE published in Brazil between 
1980 and 2013 (n = 535) is substantial. The volume of full HEE 
(n = 197) directly relevant to Brazilian settings is considerably 
higher than the number of HEE identified in other countries 
FiGURe 5 | Percentage of studies complying with recommendations for reporting of full health economic evaluation (n = 197), Brazil, 1980–2013.
FiGURe 6 | Quality of the sources of evidence used in the full health economic evaluation (n = 197), Brazil, 1980–2013.
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such as: Italy (n = 92), Colombia (n = 48), South Africa (n = 45), 
Thailand (n  =  39), Korea (n  =  33), Iran (n  =  30), Vietnam 
(n =  26), China (n =  26), Saudi Arabia (n =  10), Bangladesh 
(n = 12), Nigeria (n = 10), and Zimbabwe (n = 3) (14, 15, 17, 19, 
21, 24–28, 40). Conversely, Brazil still produces a lower number 
of HEE compared with high-income countries such as United 
Kingdom (n = 675), Canada (n = 300), German (n = 283), and 
Australia (n = 245), where economic evaluation is well established 
and formally used for regulating reimbursement policies for the 
adoption of new technologies (16, 20, 41).
BRICS (Brazil, Russia, India, and China) share in global 
wealth grew tremendously over past decade. In parallel to that, 
healthcare spending, health economic productivity, and research 
funding for health economics shifted toward low- and middle-
income countries, especially in top emerging BRICS. These 
circumstances created drivers for further development of health 
economics in these countries (8, 42–44).
In recent years in Brazil, as in other LAC countries, there has 
been increased interest in incorporating HEEs as a formal tool to 
inform decision-making processes (12). This systematic review 
reveals a steady growing trend in the number of HEE studies 
being published in the last 6 years (2008–2013). Interestingly, this 
phenomenon is also observed in Colombia (26).
The steady growth in the economic evaluation literature 
relevant at national level in Brazil—the focus of this analysis—
reached a peak in the year 2007. The reason for this may be multi-
fold; firstly, from as early as 1980 Brazilian researchers, funders, 
and public health system users have successfully promoted the 
conduct and use of HEE studies. Secondly, internationally there 
was been an increased interest in HEE studies demonstrated by 
a continuous growth of published articles and books, as well as 
the creation of several new specialist journals in this field (45). 
A third crucially important factor is some recent initiatives of 
the Brazilian Ministry of Health such as CITEC and CONITEC 
establishments. The development of this formal structure for 
regulating reimbursement policies for the adoption of new tech-
nologies, provides a strong incentive to promote the implementa-
tion and publication of a growing number of HEE studies.
Findings from systematics reviews suggest that the increase 
in the number of HEE studies published internationally may be 
related to requirements to use information from these studies to 
inform reimbursement decisions (41).
As reported in earlier systematic reviews of HEE studies in 
Latin America (17, 26, 27), our findings indicated that CEA 
was the most prevalent (39.1%, 77/197) study type for full HEE 
conducted in Brazilian settings between 1980 and 2013. This 
might be explained by the relative simplicity of the CEA approach 
compared with CUA that requires developing robust methodol-
ogy to value health state preferences.
Despite this, the current review found considerable growth in 
CUA for the Brazilian setting from 2005 onward (P = 0.028), in 
line with a growth in CUA observed in the international literature 
(41). The absolute number of CUA in Brazil (n = 40), however, is 
still small. This may, in part, be explained by the fact that CUA is 
more labor and resource intensive than CEA. In addition to this, 
the 2009 Brazilian HTA guideline gave equal weight to CEA and 
CUA (46). While CONITEC came into force in 2011 it did not 
update its methods guidelines to recommend the use of CUA. 
This is in contrast with current recommendations in a number 
of countries worldwide (e.g., Australia, Canada, Ireland, New 
Zealand, Scotland, Sweden, and United Kingdom) (47). CUA was 
indicated as the preferred type of study, only in the update of the 
Brazilian HEE guideline published in 2014 (48).
National Incorporation of Technologies in SUS has a formal 
requirement for BIA alongside a full HEE. In spite of this, the 
number of published BIA is still limited (n = 15), and most of the 
so-called BIA submitted to CONITEC are cost studies with 2–5-
year annual costs for a specific cohort instead of a real estimate 
of the financial impact of a new intervention for the Brazilian 
healthcare system. These findings are consistent with a review of 
BIA studies (49).
Like other HEE in Latin America, Africa, and South/West 
Asia most studies focused on infectious disease (14, 21, 23, 36). 
The majority of these studies focused on vaccines, driven largely 
by increased investment on CEA and related activities by major 
global health players such as Bill & Melinda Gates Foundation, 
GAVI alliance, and the World Health Organization (48).
We found that 75.5% (297/535) of the studies were published 
in medical and public heath journals. In reviews of Spanish, 
Iran, German, and South African, HEE studies covering earlier 
years of publication, the majority of studies (77, 77, 79, and 88%, 
respectively) were also published in medical journals (13, 21, 
24, 49). This high numbers may be related to lower publication 
standards in medical and public health journals when compared 
with specialized health economic journals.
Even though researchers prefer to publish their research in 
international journals, with higher impact factors, and a wider 
audience. Most of the studies (72.5%) were published in Brazilian 
journals. Among the 12% published in health economics special-
ized journals, 8% were published in a national health economic 
journal, which was not even indexed until 2013.
This may be related to publication requirements as editors 
of Brazilian journals have less stringent requirements to make 
use of international methodological guidelines as part of their 
peer reviewing processes. Consequently, articles with an inferior 
quality of reporting and equivocal methodological quality are 
published. Our data also suggest a need for improvements in 
the peer review process, especially among journals with limited 
experience publishing economic evaluations (50).
The majority (75%, 148/197) of identified full HEE studies 
were published between 2008 and 2013, and the reporting qual-
ity increased progressively during the study period (P < 0.001). 
Although overall quality of reporting was considered satisfac-
tory, the review highlighted a number of issues associated with 
the reporting and methodological quality of the included HEE 
studies.
Two issues on quality of reporting deserve further attention. 
Firstly, reporting of funding source, 56%, 110 of the 197 full 
HEE studies identified here did not state their source of funding. 
This is in line with findings from reviews on the state of HEE 
studies conducted in South Africa (45%, 49/108) (24), Nigeria 
(55%, 24/44) (21), and Zimbabwe (62%, 16/26) (19). Secondly, 
and directly related to reporting source of funding is declaring 
potential for any conflicts of interest. Only 36% of the articles 
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reported conflict of interest. As highlighted by Valachis et al. (34), 
conflicts of interest may be directly related to sources of funding. 
This is a phenomenon that has been researched by several authors 
(51–53), if studies are funded by the healthcare industry this 
could have a direct impact on the conclusion drawn. Industry-
sponsored HEE are believed to be more likely to report incremen-
tal cost-effectiveness ratios that favor products manufactured 
by the sponsor. Missing details on these two crucial pieces of 
information described above may impact on the credibility and 
transparency of results from HEE studies.
Two final points are identified as requiring further considera-
tion and recommendations for improvement, these are (1) meth-
ods for the estimation of resources quantities and unit costs and 
(2) methods for the estimation of utilities parameters. While the 
majority of studies provided a source for resource utilization and 
costs, they omitted details on the identification and quantification 
of categories of resources and estimation of unit costs. This is in 
contrast to HEE guidelines (54–56), which indicate that all the 
relevant quantities of resources should be measured in a correct 
and transparent manner, and reported separately from the prices 
(unit costs) of those resources. This lack of detailed reporting on 
the quantification of healthcare resources and methods used for 
their valuation limits the ability to replicate costing processes in 
future studies.
The final critical issue identified for discussion was the poor 
quality of information used for estimating utilities parameters. 
Authors’ often reported their main sources of information for the 
measurement and valuation of preference-based outcomes, these 
sources of evidence, however, were studies ranked as low quality. 
Many studies reported having used international data from previ-
ously published studies or expert opinion. This is in contrast with 
international guidelines on HEE which state that utility values 
obtained from other countries are, in general, not transferable 
because of cultural differences (57). Recently, in 2011, two of the 
most widely used generic preference-based utility instruments—
EQ-5D and SF-6D—were cross-cultural adapted and validated, 
in addition societal preferences weights were estimated for the 
Brazilian population in 2013 (58–61). We expect that current efforts 
to estimate Brazilian utility weight “tariffs” will increase consistency 
in quality-adjusted life year calculations in future HEE studies.
One limitation of our study was that we critiqued the report-
ing, and not necessarily the actual manner that authors conducted 
their studies. However, this review was useful to assess the practice 
of HEE in the Brazilian setting.
cONcLUSiON
This review identified that an increasing number of HEE studies 
are being conducted and published in Brazil. Their reporting 
quality has increased progressively during the study period. 
Overall, the quality of these HEE studies is satisfactory, but we 
identified key areas where significant improvements could be 
made such as: reporting of funding source, conflict of inter-
est, methods for the estimation of resources quantities and 
unit costs, methods and source of evidence to estimate utility 
parameters utilities parameters. Our findings can contribute to 
improve the way HEE studies are designed, implemented, and 
reported in Brazil.
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